Real-World Patient-Reported Outcomes in ER+/HER2- aBC/mBC

• Research type

  Research Study

• Full title

  Real-World Patient-Reported Outcomes in ER+/HER2- Advanced/Metastatic Breast Cancer

• IRAS ID

  332069

• Contact name

  Prabir Chakraborti

• Contact email

  prabirchakraborti5@gmail.com

• Sponsor organisation

  Pfizer Inc

• Duration of Study in the UK

  1 years, 4 months, 14 days

• Research summary

  There are minimal data published on the patient outcomes in the second-line advanced/metastatic breast cancer disease setting, particularly following the receipt of first-line CDK4/6i therapy. This study will generate data on disease burden using a prospective, patient-reported outcomes study approach combined with a retrospective chart review to generate data in the second-line treatment setting for ER+/HER2- advanced/metastatic breast cancer , considering patients that have progressed following first-line CDK4/6i therapy.

• REC name

  East of England - Cambridge East Research Ethics Committee

• REC reference

  23/EE/0230

• Date of REC Opinion

  4 Dec 2023

• REC opinion

  Further Information Favourable Opinion